In addition, we report that CD6‐CD318 interaction inhibits lymphocyte proliferation and survival while downregulating CD6 expression on lymphocytes in vitro and in human breast cancer tissue samples, reinforcing the role of the CD6‐CD318 axis as an immune checkpoint and highlighting the potential of itolizumab as an immune checkpoint inhibitor. This evidence concerns the gene CDCP1 and breast carcinoma.